Pharmaceutical company Eli Lilly announced Sunday it has broadened its artificial intelligence collaboration with Insilico Medicine through an agreement that could reach $2.75 billion in total value.
The expanded partnership grants Lilly exclusive global rights to develop, manufacture, and market specific oral medications that are currently undergoing preclinical testing, utilizing Insilico’s artificial intelligence platform.
According to the agreement’s structure, Insilico Medicine will collect an initial $115 million payment, with additional compensation tied to development progress, regulatory approvals, and commercial success that could push the total contract value to roughly $2.75 billion. The company will also earn percentage-based royalties from future product sales.
“By deploying AI technologies that scale from biomarkers to life models, world models of human and animal life, we can identify multi-purpose targets driving multiple diseases at the same time,” said Alex Zhavoronkov, founder and CEO of Insilico Medicine.
The pharmaceutical giant and Insilico Medicine previously established a research partnership last November, building upon their initial AI software licensing arrangement that started in 2023.
